Theralase Technologies Inc (TLTFF)

[pointofreturn]

New article:

Theralase CEO Roger White talks to Cantech Letter
APRIL 8, 2014 BY NICK WADDELL 0 COMMENTS

White: "The Theralase PDCs work by destroying only the cancerous tissue and leaving healthy tissue intact. This is why the Theralase anti-cancer technology can be a game changer and disruptive in the war against cancer."
White: “The Theralase PDCs work by destroying only the cancerous tissue and leaving healthy tissue intact. This is why the Theralase anti-cancer technology can be a game changer and disruptive in the war against cancer.”

Read more:
http://www.cantechletter.com/2014/04/roger-white-ceo-theralase-talks-cantech-letter/

Theralase completed a $3.15-million, oversubscribed private placement on November 7, 2013. Associated with that private placement, were 21-million full warrants priced at $0.20 each with a two year exercise period. Theralase plans to work with the initial investors to have them exercise their warrants in the next 90 to 120 days to allow the Company access to the $4.2-million their exercise would bring. We are also working at completing a $10 to $20 Million private placement financing round in late Q3,2014, or early in the fourth quarter of 2014 to allow the Company sufficient funds to complete the Phase 1/2a clinical study in bladder cancer in 1Q2015.
Quote
"New article, front page cantechletter.com is great. I wonder if these warrants is why the SP is so funky-flat-whack... doesn't go up on good news, doesn't go down with the market... seems to be steady support but keeps getting held down. A really active campaign they have going right now... and should be an exciting month, it should pop soon, even if just for a bit until bigger news takes us to the next levels".